Creo Medical Group (CREO) Stock Overview
Through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
CREO Community Fair Values
Create NarrativeSee what 12 others think this stock is worth. Follow their fair value or set your own to get alerts.
Creo Medical Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.11 |
| 52 Week High | UK£0.23 |
| 52 Week Low | UK£0.092 |
| Beta | 0.39 |
| 1 Month Change | -3.37% |
| 3 Month Change | -22.52% |
| 1 Year Change | -36.30% |
| 3 Year Change | -74.71% |
| 5 Year Change | -93.24% |
| Change since IPO | -86.56% |
Recent News & Updates
Creo Medical Group's (LON:CREO) Shareholders Have More To Worry About Than Lackluster Earnings
Sep 29
Recent updates
Creo Medical Group's (LON:CREO) Shareholders Have More To Worry About Than Lackluster Earnings
Sep 29
Minimally Invasive Interventions Will Capture New Global Markets
Expanding global demand and healthcare trends strongly favor Creo's advanced energy portfolio, driving sustained growth in market share, revenue, and profit margins.Revenues Working Against Creo Medical Group PLC's (LON:CREO) Share Price Following 27% Dive
Mar 09What Creo Medical Group PLC's (LON:CREO) 28% Share Price Gain Is Not Telling You
Jan 03Creo Medical Group PLC (LON:CREO) Screens Well But There Might Be A Catch
Sep 19Market Cool On Creo Medical Group PLC's (LON:CREO) Revenues Pushing Shares 26% Lower
Mar 02Revenues Tell The Story For Creo Medical Group PLC (LON:CREO) As Its Stock Soars 29%
Dec 29Is Creo Medical Group (LON:CREO) Weighed On By Its Debt Load?
Oct 06Creo Medical (LON:CREO) Is In A Good Position To Deliver On Growth Plans
Feb 03
How Many Creo Medical Limited (LON:CREO) Shares Do Institutions Own?
Dec 09Shareholder Returns
| CREO | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -3.4% | 3.1% | 0.7% |
| 1Y | -36.3% | 17.0% | 20.0% |
Return vs Industry: CREO underperformed the UK Medical Equipment industry which returned 15.5% over the past year.
Return vs Market: CREO underperformed the UK Market which returned 21.8% over the past year.
Price Volatility
| CREO volatility | |
|---|---|
| CREO Average Weekly Movement | 4.1% |
| Medical Equipment Industry Average Movement | 5.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CREO has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: CREO's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 129 | Craig Gulliford | www.creomedical.com |
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments for clinics and hospitals in the United Kingdom. It develps CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; and SpydrBlade Flex, a multi-modal endoscopic scissor-type device.
Creo Medical Group PLC Fundamentals Summary
| CREO fundamental statistics | |
|---|---|
| Market cap | UK£43.27m |
| Earnings (TTM) | UK£2.60m |
| Revenue (TTM) | UK£4.60m |
Is CREO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CREO income statement (TTM) | |
|---|---|
| Revenue | UK£4.60m |
| Cost of Revenue | UK£2.50m |
| Gross Profit | UK£2.10m |
| Other Expenses | -UK£500.00k |
| Earnings | UK£2.60m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0065 |
| Gross Margin | 45.65% |
| Net Profit Margin | 56.52% |
| Debt/Equity Ratio | 6.9% |
How did CREO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/13 01:25 |
| End of Day Share Price | 2025/11/13 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Creo Medical Group PLC is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Kane Slutzkin | Deutsche Bank |
| Jyoti Prakash | Edison Investment Research |